El-Duah M, Ofori-Kwakye K
Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana.
J Vector Borne Dis. 2012 Sep;49(3):131-9.
BACKGROUND & OBJECTIVES: The artemisinin-based antimalarial medicines are first line medicines in the treatment of severe and uncomplicated falciparum malaria. Numerous brands of these medicines manufactured in various countries are available in the Ghanaian market. The study was aimed at evaluating the authenticity and quality of selected brands of artemisinin-based antimalarial medicines marketed in Ghana.
In all, 14 artemisinin-based antimalarial medicines were purchased from pharmacies (P) and licensed chemical shops (LCSs) in the Kumasi metropolis, Ghana. Simple field tests based on colorimetry and thin layer chromatography were employed in determining the authenticity of the samples. Important quality assessment tests, namely uniformity of mass, crushing strength, disintegration time, and the percentage content of active pharmaceutical ingredients (APIs) were determined.
All the brands tested contained the stipulated APIs. Artesunate tablet AT2 failed the uniformity of mass test while artesunate tablets AT3 & AT4 as well as amodiaquine tablets AM4 & AM6 failed the crushing strength test. All the six artemether-lumefantrine tablet brands passed the uniformity of mass, crushing strength and disintegration tests. Only artemether-lumefantrine tablet brand AL1 contained the correct amount of the drugs. The other 13 artemisinin products contained either a lower (underdose) or higher (overdose) amount of the specified drug. Artesunate monotherapy tablets were readily available in pharmacies and licensed chemical shops.
INTERPRETATION & CONCLUSION: All the artemisinin-based medicines tested (except AL1) were of substandard quality. The results demonstrate the need for continuous monitoring and evaluation of the quality of artemisininbased antimalarials in the Ghanaian market. Also, the practice of artemisinin antimalarial monotherapy is prevalent in Ghana. Determined efforts should, therefore, be made to eradicate the practice to prevent the development of resistance to the artemisinins.
以青蒿素为基础的抗疟药物是治疗重症和非重症恶性疟的一线药物。加纳市场上有众多不同国家生产的此类药物品牌。本研究旨在评估加纳市场上所选青蒿素类抗疟药物品牌的真伪和质量。
总共从加纳库马西市的药店(P)和有许可证的化学药品店(LCSs)购买了14种青蒿素类抗疟药物。采用基于比色法和薄层色谱法的简单现场测试来确定样品的真伪。进行了重要的质量评估测试,即重量均匀度、抗压强度、崩解时间和活性药物成分(API)的含量百分比。
所有测试品牌均含有规定的API。青蒿琥酯片AT2重量均匀度测试不合格,而青蒿琥酯片AT3和AT4以及阿莫地喹片AM4和AM6抗压强度测试不合格。所有六个蒿甲醚 - 本芴醇片品牌的重量均匀度、抗压强度和崩解测试均合格。只有蒿甲醚 - 本芴醇片品牌AL1含有正确剂量的药物。其他13种青蒿素产品所含指定药物的量要么较低(剂量不足)要么较高(剂量过量)。青蒿琥酯单一疗法片剂在药店和有许可证的化学药品店很容易买到。
所有测试的青蒿素类药物(除AL1外)质量均不合格。结果表明需要对加纳市场上青蒿素类抗疟药物的质量进行持续监测和评估。此外,青蒿素单一疗法在加纳很普遍。因此,应下定决心根除这种做法以防止对青蒿素产生耐药性。